We previously identified the transcriptional regulator Zbtb32 as a Background: factor that can promote T cell tolerance in the Non-Obese Diabetic (NOD) mouse, a model of Type 1 diabetes. Antigen targeted to DCIR2 dendritic cells (DCs) inhibited both diabetes and effector T cell expansion in NOD in vivo mice. Furthermore, Zbtb32 was preferentially induced in autoreactive CD4 T cells stimulated by these tolerogenic DCIR2 DCs, and overexpression of Zbtb32 in islet-specific T cells inhibited the diabetes development by limiting T cell proliferation and cytokine production.
Introduction
Although some autoimmune diseases can be managed by the use of immunosuppressive drugs, current treatment options for individuals with Type 1 diabetes (T1D) are largely limited to controlling the disease symptoms instead of addressing the underlying autoimmune assault 1 . Reestablishing immune tolerance to the targeted self-antigens could provide more specific and durable treatment options 2 . The Non-Obese Diabetic (NOD) mouse strain spontaneously develops autoimmune diabetes, and can be used to identify how tolerance is defective in chronic autoimmune environments or to find potential therapies that can overcome these defects 3,4 .
Previously, we targeted self antigens to specific dendritic cell (DC) subsets by using chimeric antibodies that recognize antigen uptake receptors (either DEC205 for cDC1s 5 or DCIR2 for cDC2s) with the relevant self peptide covalently attached 6 . The entire antibody is internalized and the antigenic self peptide is then processed and presented on MHC class II. This allowed identification of DC subsets able to induce tolerance against β-islet antigens within the context of chronic autoimmunity found in NOD mice. Using this approach, we demonstrated that selfantigen presentation by DCIR2 + DCs but not DEC205 + DCs could promote self-tolerance via increased apoptosis and decreased effector functions in islet-specific CD4 T cells 6 . A gene expression analysis of the affected autoreactive T cells showed increased early expression of Zbtb32 in T cells stimulated by DCIR2 + DCs. In addition, transient overexpression of Zbtb32 in islet-specific CD4 T cells delayed diabetes development, and decreased both proliferation and IFNγ production in isletspecific CD4 + T cells 6 . Together these studies suggest T cell expression of Zbtb32 plays a role in tolerance induction in NOD mice, and could be a target for treatment.
The Zbtb32 gene (also known as ROG or PLZP) was first identified as a homologue of the leukemia oncogene PLZF (Zbtb16) 7 . Zbtb32 was then shown to act as a transcriptional repressor of GATA-3 8, 9 . Since GATA-3 regulates thymocyte development and T H 2 differentiation, Zbtb32 knockout mice were produced to test if Zbtb32 played a role in modulating lymphocyte development and response to stimuli. In three genetic backgrounds (129/SV, C57Bl6, and BALB/c), the homozygous loss of Zbtb32 significantly altered T cell responses resulting in increased proliferation, increased cytokine production, and hypersensitive responses to inflammatory stimuli [10] [11] [12] [13] . NK cells and B cells from C57Bl6 mice lacking Zbtb32 similarly displayed hyperproliferation and increased effector functions 14, 15 . Therefore, data from these knockout strains show that Zbtb32 functions as a brake for lymphocyte activation and differentiation, and is consistent with our data from transient overexpression of Zbtb32 in T cells.
To better understand the role of Zbtb32 for T cell tolerance in autoimmune NOD mice, we introduced a targeted deletion using CRISPR/CAS9 techniques. The creation of mutant NOD strains has been severely limited by the lack of a robust ES line, necessitating backcrossing knockouts made in other genetic backgrounds onto the NOD background 16, 17 . Because the region surrounding the knockout locus will retain alleles from the original strain, this can confound interpretation of such mice. NOD mice carry dozens of genetic susceptibility loci that contribute to the onset of T1D and some of those linked alleles could alter diabetes susceptibility or immune phenotype of any new mutant strain 18 . These issues can be avoided by using CRISPR/CAS9 technology to directly edit DNA in NOD embryos, an approach utilized only very recently in the NOD strain 19 . For the present study, we deleted a portion of exon 2 to cause a frameshift mutation in the Zbtb32 gene, and validated the loss of the Zbtb32 protein in our colony of NOD.Zbtb32 -/-mice. These mice were used to test our hypothesis that the transcription repressor Zbtb32 plays a critical role in the inhibition of T-cell mediated autoimmune T1D. Surprisingly, T cells from NOD.Zbtb32 -/-mice were not hyperreactive as would have been expected based on both our prior overexpression data and knockout mice in other strains. Although male NOD.Zbtb32 -/-mice showed a trend of increased diabetes incidence compared to littermate controls, the difference was not significant, and no significant difference in either time of onset or overall incidence was observed in female NOD.Zbtb32 -/-mice. Overall, most of our experiments suggested mild phenotypic changes perhaps as a result of either compensation by other family members or by effects on multiple cell types that is different on the NOD genetic background.
Methods

Mice
Non-Obese Diabetic mice (NOD, JAX #001976) were initially obtained from The Jackson Laboratory, Bar Harbor ME, and bred in the facility at NIH. Additional NOD females were regularly delivered every two weeks to compensate for the loss of breeders due to diabetes in the wildtype NOD colony. Approximately 630 NOD.Zbtb32 -/-mice (about 90 litters with an average liter size of 7) were bred during the characterization the mutant strain. All mice were housed in a specific pathogen free vivarium with a 12 h on/12 h off light cycle (6 am on and 6 pm off). The care, use, and disposition of all mice used in this study were reviewed and approved (protocol K024-DEOB-16) by the Institutional Animal Care and Use Committee of the NIDDK, NIH. Diabetes was monitored and mice were considered diabetic on the first of two blood glucose level measurements above 250 mg/dl.
Generation of knockout
The NOD.Zbtb32 -/-genetic alteration was carried out as follows: NOD female mice (6-8 weeks old) were super ovulated and mated overnight with NOD male mice (>8 weeks old). Zygotes were harvested from the ampullae of super ovulated females and
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were placed in KSOM medium (Millipore, Billerica MA) before microinjection. Microinjection was performed in M2 medium (Sigma, St Louis, MO) using a micromanipulator (Narishige) and microscope (Nikon). The second exon of the Zbtb32 gene was targeted using the two following RNA guide sequences; 5'-UACAG UUAGC GGCUA GACUC-3' and 5'-CAAUC AUGGA UCCCC CAUUG-3'. Binding sites for single guide RNA (sg RNA) are indicated in Figure 1A . The modified Cas9n enzyme with nickase activity (System Biosciences) and sgRNA were co-injected into the pronucleus and cytoplasm of 238 zygotes (1 st round 37, 2 nd round 47, and 3 rd round 154) and resulted in a total of 35 pups. The final injection concentration in the mixture was 10 ng/μl Cas9n and 5 ng/μl of each sgRNA. After injection and incubation in 5.5% CO 2 at 37°C overnight for 24 h, surviving 2-cell stage embryos were transferred to female NOD pseudopregnant recipients via oviduct transfer.
Characterization of CRISPR/CAS9n genetic alterations Genomic DNA was extracted from tail snips of the 35 21 day-old F0 mice using the DNeasy blood and tissue kit (Qiagen). The target region was PCR amplified by PuReTaq ReadyTo-Go PCR beads (GE Healthcare) followed by IndelCheck CRISPR/TALEN insertion or deletion detection system (GeneCopoeia). Successful genetic editing of the Zbtb32 gene was observed in 15 of the 35 pups. Genomic DNA from pups with evidence of deletion was further PCR amplified and subsequently cloned by TOPO T/A subcloning (Invitrogen, Carlsbad, CA) followed by DNA sequencing. Compound heterozygous null founders were bred with wildtype NOD animals to provide four potential alleles (named A, B, C, and D) for the creation of a NOD.Zbtb32 -/-colony. All four mutant alleles were sequenced to verify a successful deletion (Supplementary Table 1 ). As expected, the mutant alleles displayed a variety of deletion sizes due to differential DNA repair. Sibling crosses with matching mutant alleles were set up but, only mice carrying the mutant B allele were reliable breeders. Therefore, all NOD.Zbtb32 -/-mice described in this paper are homozygous for the B allele.
Genotyping and sequencing
For routine genotyping and sequencing, we used the following PCR primers: forward 5'-AGCTG GCCTT TGGCT TAGTT-3' and reverse 5'-CAAAG GTGGA AGGGC TTATG-3'. Binding sites for these primers in relation to the CRISPR/Cas9 deletion are indicated in Figure 1A . PCR conditions followed a typical 3-temp program; 95°C for 5 min, [95°C 30s, 55°C 30s, 72°C 45s] repeat 34 times, and finally 72°C for 10 min. The PCR results were run out on a 2% agarose gel. Single pass DNA sequencing services (ACGT, Inc., Germantown, MD) were carried out on genomic DNA using the reverse primer.
Western blotting
During dissections, mice were euthanized by CO2 asphyxiation and then the spleen was removed and placed in ice-cold PBS. Splenocytes were negatively enriched for CD4 + T cells using magnetic beads via the mouse CD4 + T Cell Isolation Kit (Miltenyi Biotech, Bergisch Gladbach, Germany) and then were incubated with Armenian Hamster anti-mouse CD3 (clone 145-2C11, Biolegend cat#100301) and Syrian Hamster anti-mouse CD28 (clone 37.51, Biolegend cat#102111) for either 14 h or 24 h at 37°C in T-cell Media (RPMI-1640+10% FBS+L-glutamine +Penn/Strep). The cells were then pelleted and lysed used RIPA buffer supplemented with Protease Inhibitor Cocktail (Roche, Indianapolis, IN). A total of 35 μg of protein was loaded into a NuPAGE 4-12% Bis-Tris gel, transferred onto nitrocellulose, blocked in 5% milk for 1 hour at 25°C, and blotted for Zbtb32 using rabbit anti-mouse sc-25358 (Santa Cruz Biotech, Santa Cruz CA) at a 1:500 dilution overnight at 4°C. The membrane was then washed prior to the addition of goat-anti-rabbit HRP (Jackson Immunoresearch cat#111-035-003) at a dilution of 1:5,000 dilution at 1 hour at 25°C. The membrane was then stripped, reblocked and reblotted for Lamin B using goat anti-mouse sc-6217 at a 1:5,000 dilution for 1 hour at 25°C. The membrane was then washed prior to the addition of donkey anti-goat HRP (Jackson Immunoresearch cat#705-035-003) at a dilution of 1:5,000 dilution for 45 minutes at 25°C. All protein bands were imaged on a BioRad ChemiDoc CCD system and processed with the BioRad Image Lab 6.0 software.
Ex vivo stimulations and cytokine staining
Splenocytes and lymphocytes were stimulated with anti-mouse CD3 (145-2C11; BioLegend, San Diego, CA). A total of 5×10 5 cells were incubated for 18 hours at 37°C in T-cell media with either 0, 10, 100, or 1000 ng of anti-CD3 in a 300 μl volume. For cytokine staining, cells were stimulated with PMA and Ionomycin in T-cell Media for 5 hours at 37°C. Brefeldin A was added to all cells for the final 4 hours of stimulation. Cells were then fixed and stained for flow cytometry. FMO staining controls were performed using a mixture of both unstimulated and stimulated cells. 
Statistical analysis
Statistical analysis for all experiments was carried out using GraphPad Prism v5. Where appropriate, statistical significance was calculated using either a Kaplan-Meier survival method (for disease incidence), or a two-way ANOVA tests for independent samples with post hoc Bonferroni comparisons for each possible pair of groups (used for all other data). Any significant differences (P < 0.05) between the two control strains are denoted with an asterisk. All dot plots show exact data points with a horizontal line denoting the average. All histograms show the average and standard deviation for the data.
Results
Using CRISPR techniques to generate knockout mutations directly in the NOD genetic background The NOD mouse is an important model for examining spontaneous and chronic autoimmune disease, but it has been difficult to obtain genetically modified NOD mice due to the lack of a robust NOD ES cell line 19 . Directly targeting mutations into the NOD genetic background via CRISPR gene editing in NOD embryos is now possible 20 . Matching sgRNAs in exon 2 of Zbtb32 ( Figure 1A and B) and CAS9n were injected into 2 cellstage embryos. Using the CAS9n with nickase activity ensures that an insertion or deletion can only occur if CAS9n binds to both sgRNAs, vastly reducing off-target events 21 . Four female mice carrying a suitable deletion were selected to be potential F0 founders (indicated in Figure 1C ) and were crossed with wildtype NOD mice to produce heterozygous mice in the F1 generation. Two of these potential F0 founders were found to be germline compound heterozygous for the loss of Zbtb32, providing up to four potential alleles (listed in Supplementary Table 1 as alleles A, B, C, and D) for the creation of a NOD.Zbtb32 -/-colony. Sibling crosses with matching mutant alleles were set up using the F1 generation. Because mice carrying the mutant B allele were the most reliable breeders, all NOD.Zbtb32 -/-mice described in this paper are homozygous for the B allele containing a 146 bp frameshift deletion.
We designed PCR primers to serve for both routine genotyping purposes (demonstrated in Figure 1D ) and as sequencing primers. Genomic sequencing on select NOD.Zbtb32 -/-mice from multiple generations verified that the deletion within the Zbtb32 gene was stable (Supplementary Figure 1) . In wildtype NOD mice, Zbtb32 was not detectable at baseline in resting CD4+ lymphocytes, but could be detected by Western blot as early as 14 hours post anti-CD3/CD28 stimulation ( Figure 1E ). No Zbtb32 protein was observed in NOD.Zbtb32 -/-mice at either baseline or post-stimulation ( Figure 1E ). The raw images for the genotyping gels and western blots seen in Figure 1 .
Diabetes incidence in NOD.Zbtb32
-/-mice To test the hypothesis that absence of Zbtb32 would increase diabetes pathogenesis in NOD mice, we monitored diabetes via blood glucose levels in NOD.Zbtb32 -/-mice and their control littermates for up to 35 weeks for both female ( Figure 2A ) and male mice ( Figure 2B ). NOD mice normally spontaneously develop hyperglycemia, between 12 and 30 weeks of age due -/-colony by weekly blood glucose monitoring for both female (A) and male (B) mice. Disease incidence rates were followed for littermate wildtype, and homozygous knockout mice. Disease incidence rates for males and females were plotted in (C).
to autoimmune destruction of the insulin secreting β-islet cells within the pancreas. The diabetes incidence rates showed no statistical differences between NOD.Zbtb32 -/-mice and their wildtype littermate controls when using a standard Kaplan-Meir survival test, but the male NOD.Zbtb32 -/-trended toward a higher than expected total diabetes incidence ( Figure 2C) . Therefore, the trend in higher male disease incidence may indicate a mild phenotype in NOD.Zbtb32 -/-mice may impact disease onset over long timescales.
Ex vivo T cell numbers and activation levels are not significantly altered in NOD.Zbtb32 -/-mice Potential differences between wildtype and Zbtb32 -/-lymphocyte phenotype of both male and female mice at 8 weeks of age were tested using flow cytometry. Activation markers on Foxp3 + T cells were measured without exogenous stimulation. As expected, higher activation was measured in the pancreaticdraining lymph nodes (pLNs) (Figure 3 ) compared to the spleen (Supplementary Figure 2) , consistent with an autoimmune reaction to antigens acquired from pancreatic tissue. However, no statistically significant differences were observed between the NOD.Zbtb32
-/-mice and their control littermates for percent CD25 + ( Figure 3A ), CD69 + ( Figure 3B ), or CD44 MFI ( Figure 3C ) (and Supplementary Figure 2A -C) . T cells from the NOD. Zbtb32 -/-pLN, but not the spleen were more variable than the wildtype for these phenotypes, and in some comparisons trend higher (e.g. elevated CD25 expression in female CTLs seen in Figure 3A ), suggesting a mild activation phenotype.
In vitro stimulation of splenocytes is not significantly altered in NOD.Zbtb32 -/-mice In previous reports describing Zbtb32 gene deletion in other genetic backgrounds, reported phenotypes included T-cell hypersensitivity, increased proliferation, and increased cytokine production [10] [11] [12] 14 . We therefore carried out parallel experiments using splenocytes from the NOD.Zbtb32 -/-mice. Splenocytes from both NOD.Zbtb32 -/-mice and NOD wildtype mice were stimulated with anti-CD3, and cell activation was assessed after 18 h by staining for surface CD69 ( Figure 4A-C Figure 5 ). Since prior reports had indicated that Zbtb32 can regulate early B cell proliferation 26 , B1 populations in the peritoneal cavity of NOD.Zbtb32 -/-mice and their wildtype controls were examined at 4 weeks of age ( Figure 5 ). NOD.Zbtb32 -/-mice trended toward fewer total B cells in their peritoneal cavity. But no statistically significant differences were observed in the proportion of B1 cells among all CD19
+ cells between wildtype NOD and NOD.Zbtb32 -/-mice (analysis not shown). Therefore, the mild diabetes phenotype and the absence of the expected T cell activation phenotype are unlikely to be due to effects on B1 cells. The raw data values and the GraphPad Prism fole for blood glucose measurements. Raw flow cytometry sample data and the FlowJo analysis file for ex vivo stimulated splenocytes, including cell proliferation and cytokine production. 
Discussion
We previously focused on Zbtb32 as a potential regulator of T cell tolerance in the NOD mouse model, and found that this transcription regulator was preferentially induced in autoreactive CD4 + T cells after interacting with tolerogenic DCIR2 + DCs, and that overexpression in T cells inhibited both diabetes and effector T cell expansion 6 . The available literature corroborated these findings but did not provide insight into how Zbtb32 might control T cell development and tolerance in a spontaneous autoimmune disease such as T1D [9] [10] [11] 27 . We initially hypothesized that the Zbtb32 -/-mutation in NOD mice would result in hyperactive T cells and increased diabetes. Instead, no significant changes in disease incidence in the NOD.Zbtb32 -/-mice were observed, and the increased T cell activation and differentiation observed in mutants from other genetic backgrounds were absent. No significant shifts in the number or percentage of the major lymphocyte populations were observed. Furthermore, we observed that the loss of Zbtb32 had no impact on intraperitoneal B1 cells, despite the fact that it is constitutively expressed in those cells in wildtype animals. In most of these readouts, a trend towards the expected phenotype was observed, suggesting a very mild phenotype, with only the long-term male disease incidence rates provided any evidence that the loss of Zbtb32 affected T1D disease pathogenesis. Although NOD females normally have higher incidence than males, this phenotype can vary greatly, and 50% incidence is within range of what we have observed for our colony (20-50% in males and 40-90% in females).
Prior investigations of Zbtb32 knockout mice in other genetic backgrounds consistently showed an activated T cell phenotype that included hypersensitivity, increased cytokine production, and increased proliferation [10] [11] [12] [13] [14] . Furthermore, our results showed that overexpression of Zbtb32 delayed diabetes onset, limited T-cell proliferation, and decreased IFNγ production from autoreactive T cells in an adoptive transfer model of T1D 6 . There are several possible reasons that may account for the observed lack of expected phenotype. One potential explanation for our unexpected results is that the CRISPR/Cas9 mediated deletion produced either an off-target effect or otherwise caused genetic instability at the deletion site. The use of CRISPR techniques in the NOD genetic background is a new approach that has, to our knowledge, only been described in two previous publications to date 19, 28 . The CRIPSR/Cas9 mediated deletion was significantly smaller than other previously engineered Zbtb32 deletions (Compare Figure 1B to Supplementary Figure 4) , but still disrupted the reading frame of the Zbtb32 gene. Our western blots ( Figure 1E ) demonstrated that the protein had been eliminated, and the use of CAS9n minimized other potential mutations. Nevertheless, we re-examined our colony for any evidence of genetic instability or off-target effects by re-sequencing archived genomic DNA from founder mice and five subsequent generations of sibling crosses and found that the mutations remained stable (Supplementary Figure 1) in every sequenced member of our NOD.Zbtb32 -/-colony. To identify potential off-target effects, we compared sequence homologies among all the transcription factors in the Zbtb family as well as sequence homologies for just the guide RNA strands used by the Cas9n enzyme. Both homology analyses indicated that only Zbtb16 was a potential target for unintended genetic editing. However, sequencing the Zbtb16 gene in multiple generations of the NOD.Zbtb32 -/-mouse colony revealed no off-target mutations of Zbtb16 (data not shown). These results therefore argue against the idea that our overall lack of phenotype can be explained by erroneous CRISPR/Cas9 activity.
Genetic backgrounds can have a dramatic effect as genetic alterations combine to either mask or exacerbate disease phenotypes 29 . Interestingly, the role of Zbtb32 in immune tolerance was examined in the BALB/c strain by using the Experimental Autoimmune Encephalitis (EAE) model. The loss of Zbtb32 in BALB/c mice had no significant impact on the EAE clinical score or timing of onset of paralysis suggest that the loss of Zbtb32, despite the observed activated T cell phenotype, was not sufficient to precipitate severe autoimmunity 11 . A rapid and induced autoimmune model like EAE differs significantly from a spontaneous, chronic disease model like NOD, but the parallel results between our findings and the findings in Kang et al.
11 suggest that, in some contexts, other genes may be able to compensate for the loss of Zbtb32. Further support for this explanation comes from an examination of regulatory transcription factors in T H 17-mediated autoimmune pathology 30 . The authors found that although Zbtb32 gene expression was highly correlated with a protective phenotype, the loss of the Zbtb32 gene in the 129/Sv background did not produce the expected hypersensitive T H 17 response and instead observed a diminished T H 17 response after repeated stimulations. Based on their gene expression data, Gaublomme et al. hypothesized that while Zbtb32 normally suppresses pro-inflammatory responses, other unidentified transcription factors continued to upregulate pro-regulatory genes and therefore mask the expected phenotype in T H 17 responses 30 . The NOD.Zbtb32 -/-mice differed from past knockout strains in terms of the T cell response. Examinations of lymphocytes from the pLNs (Figure 3 ) and the spleen (Supplementary Figure 2) revealed only mild differences between wildtype and knockout littermates in NOD mice. Considering that the target pancreatic antigens are trafficked into the pLNs and by 8 weeks of age NOD mice display chronic autoimmunity and lymphocytic infiltration in the pancreatic islets 31,32 , we had expected to find increased levels of lymphocyte activation in the pLNs. The major phenotype observed in other Zbtb32 -/-strains was a hyperreactivity to in vitro T cell stimulation, manifest in higher proliferation and cytokine production 10, 11, 14, 26 . However, T cells from NOD.Zbtb32 -/-mice showed no increase in proliferation or IFNγ production in response to in vitro stimulation.
It is possible that the lack of phenotype in the NOD genetic background, but not other backgrounds, was due to compensation from homologous proteins. The loss of Zbtb32 from birth could activate compensatory mechanisms in NOD mice that obscure any overt abnormalities in adult mice. It is even possible that a compensatory mechanism was selected for in the course of breeding NOD.Zbtb32 -/-mice. Our incidence data includes one mutant mouse from our first generation of the colony that developed hyperglycemia at an abnormally early age (8 weeks), and three out of the four mutated alleles proved to be poor breeders. Zbtb32 is constitutively expressed in the testis 33 , but its role in fertility is not clear 34 . These unexpected results could potentially be explained by compensatory mechanisms that were either already present within the NOD genetic background, or were selected for during the generation of this NOD.Zbtb32 -/-mouse colony. Therefore, an alternative approach targeting expression in adults could yield a different result.
Taken together, our results show that the systemic loss of Zbtb32 in NOD mice does not lead to a hypersensitive T cell phenotype and increased diabetes pathogenesis. Although the NOD.Zbtb32 -/-male mice displayed some increase in diabetes incidence compared to littermate controls, these trends did not reach statistical significance. Therefore, we conclude that NOD mice with the loss of Zbtb32 have a mild phenotype that may be a result of compensation by a currently unknown mechanism. In a broader context, these data do not support a major role for Zbtb32 as a target for treatment of autoimmune diabetes. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
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Supplementary Table 1. Alignment of NOD.Zbtb32 mutant alleles. The four mutant alleles of Zbtb32 that were produced by CRISPR/ Cas9 were then sequenced and aligned. Allele B was chosen to serve as the only mutation in the colony.
Click here to access the data.
Supplemental Figure 1 . The CRISPR/Cas9 deletion remained stable in the NOD.Zbtb32 colony. We archived breeder genealogies and genomic DNA from all mice in the NOD.Zbtb32 mouse colony. A genealogy of breeding cages carrying the B allele of the mutated Zbtb32 gene is depicted in (A). A total of 16 archived DNA samples were sequenced and then aligned in order to verify that the mutation remained stable in the colony (B). These archived samples included 1 founder of the B line, 13 homozygous knockout descendants, and 2 homozygous wildtype offspring.
Supplemental Figure 2. Activation markers from resting splenocytes in NOD.Zbtb32
-/-mice. We examined populations of Treg, Tcon, and CD8 + T cells in freshly dissected spleens from both male and female mice and their littermate controls. Flow cytometry was used to determine the ratio of CD25 + (A) CD69 + (B) and cell surface expression of CD44 (C) on the indicated splenocytes.
Supplemental Figure 3 . Activation markers on ex vivo-stimulated lymphocytes from pancreatic draining lymph nodes. After isolating lymphocytes from the pancreatic draining lymph nodes of NOD.Zbtb32 -/-mice and stimulating them with anti-CD3 as indicated, we stained for activation markers in both male and female mice as well as their matching controls. Flow cytometry was used to determine the ratio expressing CD25 (A-C) for CD4 + , CD8 + , and Nkp46 + splenocytes. Additionally, we measured cell proliferation in splenocytes after 48 h in response to 1000 ng of anti-CD3 (D&E).
Click here to access the data. Figure 4 . Other zbtb32 KO maps. For comparison purposes, the mutant mRNA sequences that arise from each of the previous 3 mutant strains are depicted here. The mature mRNAs contain no introns, and non-coding portions are shown as thinner than the coding portions. Each of the previous three mutants was produced by deleting large portions of the Zbtb32 gene and replacing the sequence with selection and/or reporter genes.
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No competing interests were disclosed. Defining how tolerance is lost in Type 1 diabetes (T1D) will significantly contribute to our understanding of autoimmune dysregulation and the generation of beta-cell-specific effector T cell responses. Previous studies by the Tarbell lab demonstrated that DCIR2 tolerogenic dendritic cells could promote self-tolerance to autoreactive CD4 T cells partly due to the upregulation of the transcription factor Zbtb32 in CD4 T cells. Overexpression of Zbtb32 in CD4 T cells was effective in delaying T1D by decreasing T cell proliferation and IFN-gamma synthesis. To further confirm the role of Zbtb32 in autoimmune diabetes, the current manuscript by Coley, et al. attempts to test the hypothesis that loss of Zbtb32 will exacerbate diabetogenic T cell responses and accelerate T1D in newly derived NOD.Zbtb32 mice. Contrary to their hypothesis, the data presented displays a moderate acceleration in spontaneous diabetes in male NOD.Zbtb32 mice, but no difference in female mice. In addition, there were no significant differences observed in activation markers, IFN-gamma synthesis, or proliferation between CD4, CD8, NK, and B cells in NOD and NOD.Zbtb32 mice. The manuscript is well-written, results are interesting, and the conclusions are supported by the provided data. While the majority of the data is "negative", the results are insightful and informative to the T1D research community. However, there are minor concerns that need to be addressed with the manuscript in its current form:
Zbtb32 is a negative regulator of GATA3, did the authors ever examine GATA3 expression levels and GATA3-dependent signaling pathways to determine if Th2 cytokine responses were elevated in NOD.Zbtb32 mice? The spontaneous incidence of T1D in female mice was stopped at 35 weeks of age, but the male incidence stopped at 45 weeks of age, if the female incidence was extended to the same time point, was there a difference? I agree with the authors' discussion concerning strain differences and potential compensatory mutations that may account for the absence of accelerated T1D in NOD.Zbtb32 mice in contrast to other inbred mouse models. Out of curiosity, was EAE ever induced in NOD.Zbtb32 mice to determine if this mouse may exhibit an increased susceptibility to ascending paralysis? The figure legend for 4 needs to be consistent since the symbols are different for NOD and NOD.Zbtb32 mice.
Is the work clearly and accurately presented and does it cite the current literature? Yes
Is the study design appropriate and is the work technically sound? Thank you for taking the time to review our article and for your thoughtful responses. We truly appreciate your review and will endeavor to provide satisfactory responses to each the concerns that you raised.
Query 1) Zbtb32 is a negative regulator of GATA3, did the authors ever examine GATA3 expression levels and GATA3-dependent signaling pathways to determine if Th2 cytokine responses were elevated in NOD.Zbtb32-/-mice?
Answer: It is our understanding that Zbtb32 normally inhibits the function of GATA3 by physically occupying the DNA binding site for GATA3, and not by regulating its gene expression. Consequently, we did not examine GATA3 gene expression. We did examine cytokine production in NOD.Zbtb32-/-lymphocytes (see Fig. 4 ), but did not observe any differences compared to control mice.
Query 2) The spontaneous incidence of T1D in female mice was stopped at 35 weeks of age, but the male incidence stopped at 45 weeks of age, if the female incidence was extended to the same time point, was there a difference?
Answer: We monitored most of the female mice (50 out of 55) past 35 weeks but did not encounter any cases of disease onset in females beyond 31 weeks. The figure for disease incidence in females was truncated at 35 weeks for the sake of clarity.
Query 3) I agree with the authors' discussion concerning strain differences and potential compensatory mutations that may account for the absence of accelerated T1D in NOD.Zbtb32-/-mice in contrast to other inbred mouse models. Out of curiosity, was EAE ever induced in NOD.Zbtb32-/-mice to determine if this mouse may exhibit an increased susceptibility to ascending paralysis?
Answer: No, we never attempted to induce EAE in the NOD.Zbtb32-/-mice.
Query 4) The figure legend for 4 needs to be consistent since the symbols are different for NOD and NOD.Zbtb32-/-mice. Answer: Thank you for the feedback. In Figure 4 , data is shown for 3 cell types from both wild type and knockout animals. Each cell type was assigned its own symbol, but the coloration is consistent with the genotype. All wildtype data uses black, filled symbols; all knockout data uses open symbols. We will submit a revision to make this more clear to future readers.
Thank you again for your feedback and constructive criticism.
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